PPARγ deficiency is also linked to pulmonary disorders such as asthma, lung cancer, cystic fibrosis, and inflammation, and PPARγ has been suggested to be a potential therapeutic target to treat these diseases [2]. This evidence concerns the gene PPARG and lung disorder.